Synopsis
Synopsis
0
CEP/COS
0
VMF
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. (1,1'-biphenyl)-3-carboxylic Acid, 3'-((2z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-
2. Ddl-701
3. Eltrombopag
4. Promacta
5. Revolade
6. Sb-497 115
7. Sb-497-115
8. Sb497115
1. 496775-62-3
2. Revolade
3. Promacta
4. Eltrombopag (olamine)
5. Unii-4u07f515lg
6. Sb-497115-gr
7. Eltrombopag Diethanolamine Salt
8. 496775-62-3 (olamine)
9. Eltrombopag (as Olamine)
10. 4u07f515lg
11. Sb-497115gr
12. Eltrombopag Compd With 2-aminoethanol (1:2)
13. Eltrombopag Diethanolamine Salt;sb-497115gr
14. (z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxyiic Acid;2-aminoethan-1-ol (1:2)
15. 3'-((2z)-2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene)diazanyl)-2'-hydroxybiphenyl-3-carboxylic Acid Compound With 2-aminoethanol (1:2)
16. Promacta Olamine
17. Eltrombopagolamine
18. Eltrombopag Olamine [usan:jan]
19. Promacta (tn)
20. Sb 497115gr
21. Schembl210183
22. Amy267
23. Chembl3989691
24. Schembl16207741
25. Schembl23458316
26. Eltrombopag Olamine (jan/usan)
27. Eltrombopag Olamine [jan]
28. Eltrombopag Olamine [usan]
29. Bcp07055
30. Eltrombopag Olamine [mart.]
31. Eltrombopag Olamine [who-dd]
32. Hy-15306a
33. Mfcd22380664
34. S2229
35. Akos025396658
36. Akos037515856
37. Ccg-270074
38. Cs-1566
39. Sb19102
40. Eltrombopag Olamine [orange Book]
41. 2-aminoethan-1-ol Hemi((e)-3'-(2-(2-(3,4-dimethylphenyl)-5-methyl-3-oxo-2,3-dihydro-1h-pyrazol-4-yl)hydrazono)-2'-oxo-2',3'-dihydro-[1,1'-biphenyl]-3-carboxylate)
42. Ac-26286
43. Bs-17370
44. Ft-0773802
45. D03978
46. A904098
47. Q27260489
48. Eltrombopag Compd With 2-aminoethanol (1:2) [mi]
49. (1,1'-biphenyl)-3-carboxylic Acid, 3'-((2z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene)hydrazino)-2'-hydroxy, Compound With 2-aminoethanol (1:2)
50. (1,1'-biphenyl)-3-carboxylic Acid, 3'-((2z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-, Compound With 2-aminoethanol (1:2)
51. (1,1'-biphenyl)-3-carboxylic Acid, 3'-(2-(1-(3,4-dimethylphenyl)-4,5-dihydro-3-methyl-5-oxo-1h-pyrazol-4-yl)diazenyl)-2'-hydroxy-, Compd. With 2-aminoethanol (1:2)
52. 2-aminoethan-1-ol Hemi((z)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate)
53. 2-aminoethanol (e)-3'-(2-(1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1h-pyrazol-4(5h)-ylidene)hydrazinyl)-2'-hydroxy-[1,1'-biphenyl]-3-carboxylate
54. 2-aminoethanol;3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1h-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic Acid
55. 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic Acid Bis-(monoethanolamine)
56. 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic Acid Bis-(monoethanolamine)
57. 3'-{(2z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4h-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic Acid 2-aminoethanol (1:2)
| Molecular Weight | 564.6 g/mol |
|---|---|
| Molecular Formula | C29H36N6O6 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 7 |
| Exact Mass | 564.26963289 g/mol |
| Monoisotopic Mass | 564.26963289 g/mol |
| Topological Polar Surface Area | 207 Ų |
| Heavy Atom Count | 41 |
| Formal Charge | 0 |
| Complexity | 822 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e. g. corticosteroids, immunoglobulins) (see sections 4. 2 and 5. 1).
Revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. g. corticosteroids, immunoglobulins) (see sections 4. 2 and 5. 1).
Revolade is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. 1).
Revolade is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5. 1).
B02BX05
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
About the Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With facilities conforming ...
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
About the Company : Granules is a fast-growing, vertically integrated pharma company based in Hyderabad, committed to operational excellence, quality, and customer service. It manufactures across the ...
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
About the Company : ChemWerth, established in 1982, is a US-headquartered full-service generic API company. It supplies cGMP-quality APIs to regulated markets worldwide, with exclusive partnerships fo...
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
About the Company : Nuray Chemicals Pvt Ltd, established in 2012 near Chennai, is an API manufacturer for highly regulated markets. Its state-of-the-art R&D facility specializes in synthesizing NCEs, ...
About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
About the Company : Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers cost-effective APIs with speed, supported by a skilled team. As the first Southeast Asian company to receive FDA approv...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...
About the Company : Founded by a group of highly committed Technocrats in year 2009, today Raks Pharma is a partner of choice for pharmaceutical companies across the globe to source Active Pharmaceuti...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Company : Novartis
Eltrombopag Olamine
Drug Cost (USD) : 557,676,106
Year : 2023
Prescribers : 5708
Prescriptions : 39505

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Novartis
Eltrombopag Olamine
Drug Cost (USD) : 454,825,188
Year : 2022
Prescribers : 5150
Prescriptions : 35692

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Novartis
Eltrombopag Olamine
Drug Cost (USD) : 389,486,269
Year : 2021
Prescribers : 4960
Prescriptions : 32978

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Novartis
Eltrombopag Olamine
Drug Cost (USD) : 341,789,027
Year : 2020
Prescribers : 4616
Prescriptions : 31379

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Novartis
Eltrombopag Olamine
Drug Cost (USD) : 304,352,153
Year : 2019
Prescribers : 4977
Prescriptions : 31057

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Glaxosmithkline
Eltrombopag Olamine
Drug Cost (USD) : 424,909
Year : 2018
Prescribers : 35
Prescriptions : 72

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Novartis
Eltrombopag Olamine
Drug Cost (USD) : 254,107,970
Year : 2018
Prescribers : 4752
Prescriptions : 29029

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Glaxosmithkline
Eltrombopag Olamine
Drug Cost (USD) : 2,376,341
Year : 2017
Prescribers : 179
Prescriptions : 413

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Novartis
Eltrombopag Olamine
Drug Cost (USD) : 189,364,721
Year : 2017
Prescribers : 3911
Prescriptions : 24061

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Glaxosmithkline
Eltrombopag Olamine
Drug Cost (USD) : 51,113,943
Year : 2016
Prescribers : 2229
Prescriptions : 8487

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Eltrombopag Olamine, Eltrombopag
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,738
2019 Revenue in Millions : 1,416
Growth (%) : 23

Eltrombopag Olamine, Eltrombopag
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 2,016
2020 Revenue in Millions : 1,738
Growth (%) : 16

Eltrombopag Olamine, Eltrombopag
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 2,088
2021 Revenue in Millions : 2,016
Growth (%) : 4

Eltrombopag Olamine, Eltrombopag
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 2,269
2022 Revenue in Millions : 2,088
Growth (%) : 9

Eltrombopag Olamine, Eltrombopag
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 2,216
2023 Revenue in Millions : 2,269
Growth (%) : -2

EltroMbopag diethanolamine salt
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 24.20%
2013 Revenue in Millions :
Growth (%) :

EltroMbopag diethanolamine salt
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 0
2014 Revenue in Millions : 402
Growth (%) : New Launch

Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 635
2015 Revenue in Millions : 402
Growth (%) : 58

EltroMbopag diethanolamine salt
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 867
2016 Revenue in Millions : 635
Growth (%) : 37

EltroMbopag diethanolamine salt
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 1,174
2017 Revenue in Millions : 867
Growth (%) : 35%

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
16 Mar 2026
Reply
09 Aug 2024
Reply
04 Jun 2024
Reply
29 May 2024
Reply
30 Sep 2022
Reply
09 Sep 2022
Reply
15 Jul 2022
Reply
13 May 2022
Reply
03 Apr 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
Patent Expiration Date : 2038-11-05
US Patent Number : 11072586
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 216774
Patent Use Code : U-3937
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-11-05

Patent Expiration Date : 2028-02-01
US Patent Number : 8062665*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 22291
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-02-01

Patent Expiration Date : 2027-08-01
US Patent Number : 8828430
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 22291
Patent Use Code : U-1306
Delist Requested :
Patent Use Description : TREATMENT OF THROMBOCY...
Patent Expiration Date : 2027-08-01

Patent Expiration Date : 2026-01-13
US Patent Number : 7547719*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 22291
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-01-13

Patent Expiration Date : 2026-01-13
US Patent Number : 7547719*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 207027
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-01-13

Patent Expiration Date : 2025-07-13
US Patent Number : 7547719
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 22291
Patent Use Code : U-1575
Delist Requested :
Patent Use Description : PATIENTS WITH SEVERE A...
Patent Expiration Date : 2025-07-13

Patent Expiration Date : 2025-07-13
US Patent Number : 7547719
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 22291
Patent Use Code : U-1575
Delist Requested :
Patent Use Description : PATIENTS WITH SEVERE A...
Patent Expiration Date : 2025-07-13

Patent Expiration Date : 2025-07-13
US Patent Number : 7547719
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 22291
Patent Use Code : U-930
Delist Requested :
Patent Use Description : TREATMENT OF IDIOPATHI...
Patent Expiration Date : 2025-07-13

Patent Expiration Date : 2026-01-13
US Patent Number : 7547719*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 207027
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-01-13

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
69
PharmaCompass offers a list of Eltrombopag API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Eltrombopag manufacturer or Eltrombopag supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Eltrombopag manufacturer or Eltrombopag supplier.
PharmaCompass also assists you with knowing the Eltrombopag API Price utilized in the formulation of products. Eltrombopag API Price is not always fixed or binding as the Eltrombopag Price is obtained through a variety of data sources. The Eltrombopag Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Promacta manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Promacta, including repackagers and relabelers. The FDA regulates Promacta manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Promacta API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Promacta manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Promacta supplier is an individual or a company that provides Promacta active pharmaceutical ingredient (API) or Promacta finished formulations upon request. The Promacta suppliers may include Promacta API manufacturers, exporters, distributors and traders.
click here to find a list of Promacta suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Promacta DMF (Drug Master File) is a document detailing the whole manufacturing process of Promacta active pharmaceutical ingredient (API) in detail. Different forms of Promacta DMFs exist exist since differing nations have different regulations, such as Promacta USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Promacta DMF submitted to regulatory agencies in the US is known as a USDMF. Promacta USDMF includes data on Promacta's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Promacta USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Promacta suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Promacta Drug Master File in Japan (Promacta JDMF) empowers Promacta API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Promacta JDMF during the approval evaluation for pharmaceutical products. At the time of Promacta JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Promacta suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Promacta Drug Master File in Korea (Promacta KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Promacta. The MFDS reviews the Promacta KDMF as part of the drug registration process and uses the information provided in the Promacta KDMF to evaluate the safety and efficacy of the drug.
After submitting a Promacta KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Promacta API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Promacta suppliers with KDMF on PharmaCompass.
A Promacta written confirmation (Promacta WC) is an official document issued by a regulatory agency to a Promacta manufacturer, verifying that the manufacturing facility of a Promacta active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Promacta APIs or Promacta finished pharmaceutical products to another nation, regulatory agencies frequently require a Promacta WC (written confirmation) as part of the regulatory process.
click here to find a list of Promacta suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Promacta as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Promacta API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Promacta as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Promacta and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Promacta NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Promacta suppliers with NDC on PharmaCompass.
Promacta Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Promacta GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Promacta GMP manufacturer or Promacta GMP API supplier for your needs.
A Promacta CoA (Certificate of Analysis) is a formal document that attests to Promacta's compliance with Promacta specifications and serves as a tool for batch-level quality control.
Promacta CoA mostly includes findings from lab analyses of a specific batch. For each Promacta CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Promacta may be tested according to a variety of international standards, such as European Pharmacopoeia (Promacta EP), Promacta JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Promacta USP).